Home › Multiple Myeloma › Massachusetts
Multiple Myeloma clinical trials in Massachusetts
47 studies for Multiple Myeloma are looking for participants at sites in Massachusetts.
Cities in Massachusetts
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Beth Israel Deaconess Medical Center, Boston
- BIDMC Research Pharmacy, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06152575A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Dana Farber/Harvard Cancer Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05137054A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Dana Farber / Harvard Cancer Center, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07393282A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
- Massachusetts General Hospital, Boston
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05201781A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Dana Farber Cancer Institute, Boston
- Boston University Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07258511Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
- Massachussetts General Hospital, Boston
RecruitingObservational study
Ages 10 and older · All sexes · Updated Nov 3, 2026 · NCT06323447Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07341867ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT06518551Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06433947A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07284758AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06106945A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Boston Medical Center, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06615479A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Dana-Farber Cancer Institute /ID# 271846, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06953960A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT05651932A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, Boston
- Research Site, Boston
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Oct 21, 2026 · NCT07735637D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 9, 2026 · NCT07624513AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Boston
- Research Site, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT05850234Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT06297226A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Boston
- Research Site, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Tufts Medical Center, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07518186Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05789303A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Mass General Brigham, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07116616ELISA in Relapsed/Refractory MM
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06832865Elranatamab in R/R Multiple Myeloma
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Beth-Israel Deaconess Medical Center, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT06138275Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Dana Farber Cancer institution, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT06375044A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07075185Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Tufts Medical Center, Boston
- Tufts Medical Center Cancer Center Stoneham, Stoneham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04566328A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT05714839A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Boston Medical Center, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06292780Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT05469893A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT06121843Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT02343042Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
- Dana-Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Jun 5, 2026 · NCT03858205DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 8, 2026 · NCT07377435A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 7, 2026 · NCT06799026Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 13 and older · All sexes · Updated May 5, 2026 · NCT04771572A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT06679101Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
- Massachusetts General Hospital Cancer Center, Boston
Recruiting
Ages 18 and older · All sexes · Updated Apr 21, 2026 · NCT05646576Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT07032714From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.